the problem
Demand Exists — But It’s Fragmented, Delayed, or Lost
Traditional Channels
Coverage Constraints Suppress Utilization Across High-Spend Therapies
Prior authorization and step therapy delay therapy initiation
Rebate-driven formularies limit consistent access
Coverage variability reduces the addressable patient population
Time-to-therapy friction leads to patient drop-off
Cash Pay Market
Significant Demand Across Major Spend Categories Remains Uncaptured
Millions of clinically eligible patients lack coverage
High out-of-pocket costs suppress initiation and persistence
No structured aggregation of demand
Limited manufacturer visibility into this segment
The andel model
A New, Controlled Access Channel for High-Spend Therapies
Andel aggregates employer-sponsored demand and connects it directly to manufacturers through a structured channel designed to expand utilization across therapies driving a majority of pharmacy spend.
Additive to existing channels—not a replacement
why andel works for pharma
Designed to Expand Utilization Across Top Spend Categories
Incremental, Not Cannibalistic
Targets patients not accessing therapy through traditional channels
Predictable Demand
Aggregated employer base creates stable, forecastable utilization
Faster Time-to-Therapy
Removes administrative friction that delays initiation
Improved Adherence Potential
Lower patient cost burden supports persistence
Channel Visibility
Structured access to demand across high-spend therapies
Therapeutic Areas
Focused on Categories Responsible for the Largest Share of Pharmacy Spend
Weight Loss / Metabolic
Large uncovered population with significant demand elasticity
LOE / Post-Exclusivity Brands
Opportunity to sustain utilization across therapies driving a majority of pharmacy spend
Arthritis & Inflammatory Conditions
High-cost specialty categories with delayed therapy initiation
Neurology (Epilepsy, Migraine)
Chronic therapies where adherence drives outcomes and spend
Immunology / Autoimmune
High-friction access pathways and substantial unmet demand
How Andel fits
Complementary across therapies driving a majority of pharmacy spend
Channel
Role
Limitation
Andel Advantage
Employer-Enabled Medication Access Platform
Incremental channel
—
Structured demand across high-spend therapies
PBMs/Insurance
Core covered lives
Access restrictions
No utilization management friction
Copay Programs
Cost offsets
Limited to insured populations
Works outside insurance
The signals are clear
Growing Demand Across Major Spend Categories
Employers representing millions of covered lives seeking solutions
Strong demand across therapies driving a majority of pharmacy spend
Increasing pressure to expand access without increasing premiums